Results: The quantities of a phylotype with 97% similarity to Coprococcus eutactus and a phylotype

with 85% similarity to Clostridium thermosuccinogenes were significantly reduced (P = 0.001 and 0.019 respectively) while the amounts of Collinsella aerofaciens and B. intestinalis-like phylotype were increased (P = 0.053 and 0.052 respectively) in IBS-D patients than that in controls. Higher levels of Bacteroides intestinalis-like phylotype (P = 0.059) and lower levels of Bifidobacterium spp. (P = 0.074) were present in IBS-D patients than in RG7204 datasheet comorbid patients. In female IBS-D patients, Veillonella spp. was significantly higher than in male patients (P = 0.001). Meanwhile, it was also higher than that in female controls (P = 0.009); but was lower in male IBS-D patients when compared with male controls (P = 0.046). Desulfovibrio desulfuricans was significantly more abundant (P = 0.017) in male comorbid patients than in controls. Lactobacillus and Veillonella spp. were significantly more abundant (P = 0.029 Abiraterone solubility dmso and 0.046 respectively) in female depression or anxiety patients than that in controls. Conclusion: Our molecular data indicate that gender-related quantitative differences

exist in specific bacterial phylotypes in the microbiota among IBS-D, mental disorders and comorbid patients. The relationship between fecal microbiota and psychological comorbidity need to be studied further. Key Word(s): 1. fecal microbiota; 2. IBS; 3. psycho-comorbidity; Presenting Author: SUNNYHEI WONG Additional Authors: HO YEE HIRAI WONG, FRANCISKL CHAN, JUSTINCY WU, SIEWC NG Corresponding Author: SUNNYHEI WONG, SIEWC NG Affiliations: Institute of Digestive Disease Objective: Screening for tuberculosis is mandatory before Carnitine palmitoyltransferase II the initiation of anti-tumour necrosis

factor therapy in patients with immune mediated inflammatory diseases (IMID). Immunosuppressive therapy (IST) may affect the precision of Tuberculin skin test (TST) but the effect of IST on Interferon Gamma Release Assay (IGRA) in IMID is not clear. We conducted a meta-analysis to evaluate the impact of IST on IGRA results in IMID subjects. Methods: Publications in English and non-English literatures (OVID, MEDLINE and EMBASE) and abstracts in major international conferences were searched for clinical studies that have assessed IGRA in IMID. Outcome measures included the proportion of patients with positive IGRA based on the use of IST. Results: Of 38 studies that had made a comparison between IGRA and TST among IMID subjects, six studies fulfilling search criteria encompassing 1,375 subjects were included for analysis. A total of 556 individuals (40.4%) were male. The mean and median of Cohen’s κ-statistic was 0.28 and 0.30 (range -0.03 to 0.55), respectively. Using a fixed effect model of analysis, the overall odds ratio for a positive IGRA result in IMID patients receiving IST was 0.67 (95% CI = 0.47–0.95, p = 0.025).